List of Excipients in Branded Drug 25% DEXTROSE INFANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA Health First	25% DEXTROSE INFANT	25% dextrose infant	51662-1213	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA Health First	25% DEXTROSE INFANT	25% dextrose infant	51662-1213	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA Health First	25% DEXTROSE INFANT	25% dextrose infant	51662-1213	WATER

25% Dextrose Infant Excipient Strategy, Formulation Risks, and Commercial Opportunities

Last updated: August 24, 2026

25% Dextrose Injection for infant hypoglycemia is a mature, low-complexity sterile injectable category. The active ingredient is dextrose, typically supplied at 250 mg/mL in Water for Injection. Commercial differentiation is more likely to come from preservative-free presentation, dosing accuracy, container design, stability, supply reliability, and neonatal-use labeling than from a novel excipient system.

The main opportunity is a ready-to-administer, single-dose neonatal presentation that reduces dilution, calculation, transfer, and extravasation risks. Traditional formulation patents are unlikely to create a strong barrier because the core composition is pharmacopeial and widely available. Device, packaging, manufacturing, and workflow patents may provide more defensible protection.

What is 25% Dextrose Injection for infants?

25% Dextrose Injection contains 25 g of dextrose per 100 mL, equivalent to 250 mg/mL.

Attribute	Typical value
Active ingredient	Dextrose, generally dextrose monohydrate
Strength	25% w/v
Concentration	250 mg/mL
50 mL dose container	12.5 g dextrose
100 mL container	25 g dextrose
Route	Intravenous administration
Primary use	Treatment of acute hypoglycemia or glucose deficiency
Product type	Sterile injectable solution
Key excipient	Water for Injection
Approximate tonicity	Highly hypertonic
Primary patient risk	Extravasation, hyperglycemia, hyperosmolar injury

Dextrose 25% is hypertonic and can cause venous irritation or tissue injury if administered outside the vein. Infant labeling often includes restrictions on concentration, route, dilution, infusion rate, and monitoring. Product-specific labeling controls the permitted use and dose.[1][2]

What excipients are used in 25% Dextrose Injection?

The preferred excipient strategy is minimal: Water for Injection as the vehicle, with pH adjustment only where required by the product specification.

Core formulation

A representative formulation contains:

Component	Function	Commercial and regulatory relevance
Dextrose	Active osmotic and metabolic agent	Must meet compendial and injectable-quality requirements
Water for Injection	Vehicle	Must meet USP sterile water requirements
Hydrochloric acid or sodium hydroxide	pH adjustment, if used	May be present in small quantity and should be declared according to applicable requirements
Nitrogen overlay, where used	Oxygen reduction in headspace	Process aid rather than therapeutic excipient; relevant to oxidation control
Container closure system	Sterility and stability protection	Important source of extractables, leachables, and particulate risk

The formulation should generally avoid antimicrobial preservatives. Benzyl alcohol, parabens, phenol, chlorobutanol, and similar preservatives create avoidable neonatal safety and regulatory concerns. FDA labeling for injectable products emphasizes the need to consider preservative exposure in neonates and pediatric patients.[1][3]

Why a low-excipient formulation is commercially attractive

A short ingredient list can support:

• Lower neonatal exposure to unnecessary chemicals.
• Simpler toxicology and compatibility packages.
• Easier pharmaceutical equivalence arguments for a generic injectable.
• Lower risk of excipient-related labeling restrictions.
• Better hospital pharmacy acceptance.
• Reduced risk of precipitation or interaction with infusion components.

The tradeoff is that the formulation has fewer conventional levers for improving stability, viscosity, antimicrobial protection, or differentiation. The product therefore depends heavily on container closure integrity, aseptic processing, sterilization strategy, and dose presentation.

What excipient risks matter most in neonatal dextrose products?

The primary risk is often attributed to the dextrose concentration, but excipients and packaging can affect safety, stability, and administration quality.

pH and degradation

Dextrose solutions can undergo degradation reactions, including formation of acidic degradation products and color changes. Heat exposure and prolonged storage can accelerate these reactions. The manufacturer should control:

• Initial pH and pH drift.
• Color and visible particles.
• Dextrose assay.
• Degradation products.
• Sterility and bacterial endotoxins.
• Container closure integrity.

pH adjustment should be minimized because excessive acid or base can increase compatibility concerns and complicate formulation disclosure. A narrow, justified pH target is preferable to a broad adjustment range.

Osmolality and extravasation

25% Dextrose Injection is strongly hyperosmotic. The risk profile supports product designs that reduce unnecessary handling and prevent accidental administration of concentrated solution through inappropriate access.

Commercially relevant controls include:

• Clear concentration labeling.
• Large-print neonatal dosing information.
• A non-connectable or connector-compatible presentation where appropriate.
• Dose-volume markings.
• Syringe-based delivery for small-volume administration.
• Instructions for dilution when peripheral administration is restricted.
• Compatibility information for neonatal infusion systems.

A novel excipient cannot eliminate the fundamental osmotic risk. Product value comes from reducing medication-use errors and improving administration control.

Preservative and antimicrobial strategy

A preservative-free, single-dose product is the strongest default for neonatal positioning. Multidose formats may lower packaging cost but introduce repeated-access, contamination, and preservative-exposure concerns.

For an infant-focused product, the commercial hierarchy is generally:

1. Preservative-free, single-dose syringe.
2. Preservative-free, single-dose vial.
3. Preservative-free small-volume bag.
4. Multidose or preserved format only where a clear institutional use case exists.

What formulations are protected by patents?

The basic 25% dextrose formulation is unlikely to support a broad, high-value composition patent because dextrose, Water for Injection, and conventional pH adjustment are established pharmaceutical materials.

Potential patentable areas include:

IP category	Potential claim subject	Expected strength
Formulation	Narrow stability range, degradation control, or compatibility profile	Low to moderate unless technically unexpected
Excipient system	Specific antioxidant, buffer, or stabilizer combination	Moderate if supported by unexpected stability and neonatal safety data
Container	Syringe, vial, or bag with specialized closure or material composition	Moderate
Device	Dose-limiting connector, administration interface, or neonatal delivery system	Moderate to strong if difficult to design around
Manufacturing	Aseptic filling, terminal sterilization, or low-endotoxin process	Moderate, although trade-secret protection may be preferable
Method of use	Specific dosing or dilution protocol for neonatal hypoglycemia	Limited to moderate, subject to prior art and eligibility
Packaging	Unit-dose labeling, tamper evidence, or oxygen-control system	Low to moderate

The strongest defensible strategy is likely a layered portfolio combining formulation, container closure, delivery device, manufacturing process, and human-factors design. A single patent directed to “25% dextrose in Water for Injection” would face substantial prior-art and obviousness pressure.

What is the FDA regulatory status of 25% Dextrose Injection?

25% Dextrose Injection is an established prescription sterile injectable category regulated as a drug product. Products may be marketed through different FDA pathways depending on the reference product, approved application, labeling, and product-specific requirements.

Regulatory issue	Relevance
FDA drug approval	Required for commercial distribution
505(b)(2) pathway	Potentially relevant for a modified presentation, delivery system, or new dosing approach
ANDA pathway	Potentially relevant for a therapeutically equivalent generic product
NDA pathway	Relevant for a new formulation, delivery system, or clinical positioning
USP compliance	Important for dextrose, Water for Injection, sterility, and related quality attributes
cGMP compliance	Required for sterile manufacturing and quality systems
Pediatric labeling	Critical for infant dosing, dilution, administration, and warnings
Human factors	Increasingly relevant for prefilled syringes and neonatal-use devices

The regulatory classification depends on the exact product and reference listed drug. A developer should avoid assuming that a new syringe or administration component is automatically eligible for a simple ANDA. A material change in delivery method, dose control, or labeling can affect the pathway.

What is the Orange Book status of 25% Dextrose Injection?

The Orange Book status must be assessed at the individual product and application-number level. The category does not itself establish a single Orange Book listing or patent profile.

For a marketed product, the relevant review should identify:

• Reference listed drug status.
• Application number.
• Strength and dosage form.
• Therapeutic equivalence code.
• Listed patents, if any.
• Pediatric exclusivity.
• Regulatory exclusivity.
• Whether the product is an NDA, ANDA, or other approved application.

Because dextrose injection is an old and widely marketed sterile product, commercial barriers are more likely to arise from manufacturing scale, shortage risk, supplier qualification, and hospital contracting than from Orange Book patents. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and patent-listing data should be reviewed for the specific product under consideration.[4]

When does 25% Dextrose lose exclusivity?

The underlying dextrose composition has no meaningful modern exclusivity period comparable to a new chemical entity. Any remaining exclusivity would attach to a specific approved product, indication, formulation, device, or regulatory application.

Potential exclusivity categories include:

Exclusivity type	Likely relevance
New chemical entity exclusivity	Not relevant to dextrose
Orphan-drug exclusivity	Generally not relevant to routine neonatal hypoglycemia
Pediatric exclusivity	Possible only if separately awarded for qualifying FDA studies
New formulation exclusivity	Possible for a materially new formulation or delivery system
New clinical investigation exclusivity	Possible in limited 505(b)(2) circumstances
Patent exclusivity	Product-specific; likely limited for the basic formulation
Market exclusivity from settlement	Depends on litigation and agreement terms

The practical loss-of-exclusivity question is therefore less about a single date and more about whether a competitor can develop an approved, therapeutically equivalent, reliably manufactured product.

Which companies are competing in 25% Dextrose Injection?

The market has historically included major hospital injectable manufacturers, generic drug companies, and outsourcing or specialty sterile manufacturers. Competitive participation can vary by national shortage conditions, discontinuations, acquisitions, and product availability.

The main competitive groups are:

• Large parenteral manufacturers with hospital contracts.
• Generic injectable companies with ANDA portfolios.
• Contract development and manufacturing organizations.
• Pharmacy compounding facilities operating under applicable state and federal requirements.
• Device companies supplying prefilled syringe platforms.

Competitive advantage usually depends on:

• Reliable supply of sterile product.
• Low defect and recall rates.
• National distribution.
• Hospital group purchasing organization access.
• Unit-dose convenience.
• Pricing and contract terms.
• Ability to maintain production during injectable shortages.

A new entrant with no formulation differentiation may struggle to displace established suppliers. A differentiated neonatal syringe can justify premium pricing if it reduces preparation time and medication-error exposure.

What commercial opportunities exist for excipient and presentation innovation?

Preservative-free prefilled syringes

The most direct opportunity is a small-volume, preservative-free, ready-to-administer syringe. Benefits include:

• Lower preparation burden.
• Reduced vial access and transfer steps.
• Better dose-volume accuracy.
• Lower contamination risk.
• Faster response in emergency neonatal care.

The syringe must address extractables and leachables, silicone oil, tungsten residues where applicable, stopper compatibility, plunger force, dose accuracy, and long-term container closure integrity.

Unit-dose vials

Vials remain commercially relevant where institutions prefer pharmacy-controlled preparation or need flexible withdrawal volumes. A differentiated vial could use:

• Low-sorption elastomer closures.
• Clear, high-contrast labeling.
• Bar-code serialization.
• Smaller fill volumes tailored to neonatal dosing.
• Packaging that prevents concentration confusion with 10%, 20%, or 50% dextrose.

Small-volume infusion bags

A 25% dextrose small-volume bag may target intensive-care settings requiring controlled infusion rather than emergency bolus administration. The principal commercial issue is whether the bag’s convenience outweighs the cost and handling burden of a syringe or vial.

Dual-concentration product families

A manufacturer could build a neonatal glucose portfolio around 10%, 12.5%, 20%, and 25% concentrations. The opportunity is operational rather than purely pharmaceutical: standardized labeling, bar codes, connectors, and dosing tools can reduce selection errors.

The risk is that similar packaging across concentrations may increase wrong-product selection. Human-factors testing and high-contrast differentiation are essential.

Low-extractables container systems

A container system designed for neonatal use may have value where it demonstrates:

• Lower release of organic extractables.
• Lower particulate burden.
• Reduced oxygen transmission.
• Better color stability.
• Improved closure integrity after shipping and storage.

Claims should be tied to measurable performance rather than general “neonatal safety” language.

How strong is the patent estate for 25% Dextrose Infant?

The patent estate is likely weak for the basic drug formulation and stronger for selected delivery and manufacturing features.

Estate component	Assessment
Basic 25% dextrose composition	Weak
Water-for-Injection vehicle	Weak
Preservative-free positioning	Usually difficult to patent broadly
Prefilled syringe architecture	Moderate
Neonatal dose-control device	Moderate to potentially strong
Container closure and materials	Moderate
Specific stability-enhancing formulation	Moderate if technically supported
Manufacturing process	Moderate; trade secret may be more effective
Method-of-use claims	Limited by prior art and patentability standards
Trademark and packaging trade dress	Commercially useful but not substitute patent protection

A freedom-to-operate review should focus on syringe platforms, proprietary connectors, elastomer closures, filling equipment, and packaging systems. The active ingredient itself is unlikely to create material blocking risk.

What generic entry risks exist for 25% Dextrose Injection?

Generic entry risk is high for conventional vials and bags because:

• The active ingredient is established.
• The formulation is simple.
• Clinical differentiation is limited.
• Substitution may be available through therapeutic-equivalence mechanisms.
• Hospitals often treat the product as a commodity injectable.

Risk decreases when a product has:

• A proprietary administration device.
• A unique container closure system.
• An approved indication or dosing protocol supported by new clinical data.
• A protected stability profile.
• A complex combination of drug and device functions.
• Reliable supply during a shortage.
• Exclusive distribution or institutional contracts.

A premium product must show measurable workflow or safety value. “Preservative-free” alone may support positioning but generally does not create a durable barrier unless linked to a differentiated delivery system or regulatory claim.

What patent litigation and Paragraph IV challenges affect the product?

The basic 25% dextrose category is not commonly associated with major, durable Paragraph IV litigation comparable to branded oncology, immunology, or metabolic drugs. Any Paragraph IV challenge would be directed to a specific listed product and patent, not to dextrose as a molecule.

Relevant litigation risks include:

• Patent claims covering a prefilled syringe.
• Device patents covering a neonatal connector.
• Container-closure patents.
• Formulation patents directed to degradation control.
• Method-of-use claims involving dosing or dilution.
• Patent disputes over manufacturing processes.

For a conventional product, litigation exposure is likely lower than commercial execution risk. For a device-enabled product, the reverse can apply: the drug is simple, but the delivery architecture may create freedom-to-operate issues.

How does 25% Dextrose compare with competing glucose concentrations?

Product	Typical commercial role	Key advantage	Key risk
Dextrose 10%	General neonatal glucose support and infusion	Lower osmotic burden	Larger volumes may be required
Dextrose 12.5%	Intermediate neonatal concentration	Balance of concentration and tolerability	May require dilution or specialized use
Dextrose 20%	Higher-concentration rescue or infusion use	Lower volume than 10% or 12.5%	Greater osmotic and extravasation risk
Dextrose 25%	Concentrated treatment or emergency use	High glucose delivery in small volume	Administration injury and dosing errors
Dextrose 50%	Primarily adult emergency use	Very high glucose concentration	Generally unsuitable for routine infant use

A neonatal commercial strategy should avoid presenting 25% dextrose as interchangeable with lower concentrations. The product has a narrower administration and safety profile, and packaging must make that distinction obvious.[1][2]

What manufacturing and IP barriers affect market entry?

Sterile manufacturing is the central operational barrier. A developer needs validated control over:

• Raw-material bioburden.
• Water systems.
• Dextrose dissolution and mixing.
• Particulate control.
• Endotoxin levels.
• Aseptic filling or validated sterilization.
• Container closure integrity.
• Shipping and temperature excursions.
• Visual inspection.
• Stability-indicating analytical methods.

Dextrose solutions may present challenges related to discoloration and degradation during heat exposure. The preferred process depends on container compatibility, terminal sterilization feasibility, and product stability.

A commercially credible launch requires more than an approved formula. Hospitals evaluate shortage history, lot-release performance, bar-code integration, recalls, delivery reliability, and contract support. Manufacturing know-how and supply-chain execution may therefore provide more protection than a narrow formulation patent.

What revenue exposure and market economics apply?

25% Dextrose Injection is generally a low-price, high-volume hospital product rather than a high-margin specialty drug. Revenue exposure is concentrated in:

• Emergency departments.
• Neonatal intensive-care units.
• Pediatric intensive-care units.
• Hospital pharmacies.
• Ambulance and emergency response systems.
• Government and institutional procurement.

The commercial model changes materially by presentation:

Presentation	Likely price positioning	Main buyer value
Standard vial	Commodity to low premium	Flexible use and low acquisition cost
Small-volume bag	Moderate premium	Infusion convenience
Prefilled syringe	Premium	Speed, accuracy, and reduced preparation
Device-integrated syringe	Highest potential premium	Workflow control and error reduction

The addressable revenue opportunity is more attractive for a portfolio of neonatal and emergency glucose products than for a single 25% concentration. A standardized product family can increase contracting value and reduce hospital inventory complexity.

Key Takeaways

• 25% Dextrose Injection contains 250 mg/mL dextrose and is a highly hypertonic sterile injectable used in selected infant and pediatric settings.
• The preferred excipient strategy is minimal: dextrose, Water for Injection, and limited pH adjustment where necessary.
• Preservatives should generally be avoided in infant-focused products, particularly in multidose formats.
• The strongest commercial opportunity is a preservative-free, ready-to-administer prefilled syringe with neonatal-appropriate labeling and dose control.
• The basic formulation has limited patent strength because its composition is established and readily reproducible.
• Device, container-closure, manufacturing, and workflow claims offer better IP opportunities than broad composition claims.
• Generic entry risk is high for standard vials and bags.
• Regulatory and commercial success depends on sterile manufacturing, container integrity, supply reliability, and medication-use design.
• A broader glucose-concentration portfolio may create more value than a standalone 25% product.
• Product-specific Orange Book, patent, exclusivity, and litigation conclusions require review of the individual approved application and listed product.

FAQs

Can a preservative be added to 25% Dextrose Injection for infants?

A preservative can create formulation and regulatory complications. A preservative-free single-dose presentation is generally the more commercially defensible neonatal strategy.

Is 25% Dextrose Injection suitable for peripheral intravenous administration?

Suitability depends on the product label, access site, dilution instructions, infusion rate, and clinical circumstances. Its high osmolarity creates a substantial extravasation and venous-injury concern.

Can 25% Dextrose be protected with a new excipient patent?

Possibly, but broad claims are unlikely to be strong. The best prospects involve a specific stabilizing system that produces unexpected improvements in degradation, compatibility, or shelf life.

Would a prefilled syringe require a new FDA application?

The regulatory pathway depends on the reference product, device configuration, labeling, and extent of formulation or administration changes. A new presentation may require more than a simple manufacturing change.

Is dextrose 25% a biosimilar product?

No. Dextrose is a small-molecule drug product, not a biologic. Biosimilar approval and interchangeability rules do not apply.

References

1. U.S. Food and Drug Administration. (n.d.). Dextrose injection prescribing information. FDA Drugs@FDA and product labeling database.

2. U.S. National Library of Medicine. (n.d.). Dextrose injection, USP: DailyMed labeling. DailyMed.

3. U.S. Food and Drug Administration. (2015). Guidance for industry: Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.